Tvardi Therapeutics, Inc. (TVRD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tvardi Therapeutics, Inc. (TVRD) has a cash flow conversion efficiency ratio of -0.404x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.86 Million) by net assets ($14.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TVRD equity financing ratio to measure how much of total assets are equity-financed.
Tvardi Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Tvardi Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Tvardi Therapeutics, Inc. to evaluate the quality of earnings relative to operating cash generation.
Tvardi Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tvardi Therapeutics, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aiptek International Inc
TW:6225
|
0.013x |
|
Marti Otel Isletmeleri AS
IS:MARTI
|
-0.004x |
|
BRIDGETEC Corp
KQ:064480
|
-0.010x |
|
Hansol Homedec
KO:025750
|
0.035x |
|
Australis Oil & Gas Ltd
AU:ATS
|
0.083x |
|
L&P Global Berhad
KLSE:0268
|
0.032x |
|
Scanwolf Corporation Bhd
KLSE:7239
|
-0.163x |
|
Wiscom
KO:024070
|
-0.034x |
Annual Cash Flow Conversion Efficiency for Tvardi Therapeutics, Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Tvardi Therapeutics, Inc. from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see TVRD stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $20.95 Million | $-23.50 Million | -1.122x | -108.46% |
| 2024-12-31 | $-4.59 Million | $-60.92 Million | 13.263x | +3811.96% |
| 2023-12-31 | $-62.06 Million | $-21.04 Million | 0.339x | -14.51% |
| 2022-12-31 | $-45.05 Million | $-17.87 Million | 0.397x | +250.16% |
| 2021-12-31 | $227.52 Million | $-60.09 Million | -0.264x | -1098.46% |
| 2020-12-31 | $249.00 Million | $-5.49 Million | -0.022x | -- |
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical d… Read more